Submitted by Catherine Atkins on Tue, 02/09/2025 - 16:49
University of Cambridge spinout Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company, has announced a first close of $44 million in its Series B financing round to accelerate its ongoing US expansion.
Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory oesophageal conditions.
Instrumental in the founding of Cyted Health was Professor Rebecca Fitzgerald, Director of the Early Cancer Institute and Head of the Department of Oncology at the University of Cambridge.
Rebecca commented: "As an inventor of this technology and a co-founder of Cyted Health I am absolutely thrilled that we now have the runway to develop and implement our test for earlier diagnosis of cancer of the oesophagus. This is fantastic news for patients and the UK economy."
The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests. Cyted’s existing platform consists of EndoSign®, an FDA 510(k)-cleared device enabling minimally invasive collection of oesophageal cells, and advanced biomarker molecular testing for the detection of oesophageal conditions.
Cyted’s technology has already demonstrated significant success across the UK’s National Health Service, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving unmatched patient acceptability and real-world clinical impact. Oesophageal cancer is considered one of the deadliest cancers globally, with a survival rate of only 20%.
“This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting oesophageal diseases earlier,” said Marcel Gehrung, CEO and Co-founder of Cyted Health. “This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”
UK Science Minister Lord Vallance said: "I am pleased to see the British Business Bank back Cyted - a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people's lives. Life sciences form a critical part of this Government's ambitions for both the economy and healthcare - and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success.”
Cyted’s Series B financing round follows the recent launch of Cyted's DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025. This study will validate clinical performance of Cyted’s newest assays and molecular tests for the detection of oesophageal conditions using EndoSign®.